Biologic IVD premarket review could begin without ELA data, Abbott says.
This article was originally published in The Gray Sheet
Executive Summary
IVD PRODUCT LICENSE APPLICATIONS: FDA FILING WITHOUT FACILITY DATA should be allowed under FDA biologics regulations, Abbott Diagnostics says in Feb. 3 comments to the agency. Changing the regulations to allow the filing of PLAs for in vitro diagnostic products while manufacturers collect facility and equipment validation data for the establishment licensing application (ELA) could reduce the time it takes manufacturers to file an application by six to 12 months, Matt Klamrzynski, director of Abbott Diagnostics Division regulatory affairs, said.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.